On June 9, Tiachen Bio-B rose 6.37% in regular trading, trading at 145.1 HKD/share, with trading volume of 17.38 million HKD. The stock has accumulated a premium of approximately 51% over its IPO price of 96.06 HKD since listing on June 5.

On the news front, Tiachen Bio-B officially debuted on the Hong Kong Stock Exchange on June 5, where its Hong Kong public offering tranche received an extraordinary 4,762.58x oversubscription with only a 2% one-lot allocation rate, reflecting extreme investor demand. On its first trading day, the stock surged over 50%, with intraday highs exceeding 60% above the offer price. The sustained upward momentum reflects continued market enthusiasm following one of the most heavily oversubscribed IPOs in the Hong Kong market this year.

Tiachen Bio-B is a clinical-stage biopharmaceutical company focused on the discovery and development of biologics for allergic and autoimmune diseases. Its core product LP-003, an anti-IgE antibody, has initiated eight clinical trials in China. The company raised net proceeds of approximately 1.255 billion HKD, with about 75% earmarked for R&D and commercialization of its core pipeline. Notable cornerstone investors include OrbiMed, Value Partners, Rui Yuan Fund, and Huatai Capital.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)